falsefalse

Expanding on Treatment Trends in Platinum-Resistant Ovarian Cancer - Episode 2

MIRASOL Trial: Final OS Data for Mirvetuximab Soravtansine in FRa+ Platinum-Resistant Ovarian Cancer

,

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on final overall survival data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Current Treatment Approaches and Challenges in Platinum-Resistant Ovarian Cancer
    Now Viewing
    EP. 2: MIRASOL Trial: Final OS Data for Mirvetuximab Soravtansine in FRa+ Platinum-Resistant Ovarian Cancer
    EP. 3: PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer
    EP. 4: Exploring Other Potential Roles for Mirvetuximab Soravtansine in Ovarian Cancer
    EP. 5: Highlighting Key Ovarian Cancer Data from the 2025 SGO Annual Meeting
    EP. 6: Ongoing Research to Watch in Ovarian Cancer in 2025

    Related Content:

    NYU Langone's Perlmutter Cancer CenterExpanding on Treatment Trends in Platinum-Resistant Ovarian CancerOncLive News Network®Ovarian Cancer
    SON-1010 Plus Atezolizumab Is Safe, Displays Preliminary Efficacy in Platinum-Resistant Ovarian Cancer
    Dr Konstantinopoulos on Responses With Metformin Plus Letrozole/Abemaciclib in ER+ Endometriod Endometrial Cancer
    Dr Myers on Mitigation Strategies for Ocular AEs in Platinum-Resistant Ovarian Cancer
    x